Skip to main content

Technologies & Platforms

By investing in research and fostering a passionate environment devoted to innovation, we’re able to discover and create products that address patients’ most pressing health needs. Our portfolio of leading medicines, together with deep expertise across key areas of health and a robust pipeline of promising compounds, helps us make a difference for patients around the world.

Our Passion Helps Patients

Innovation is the cornerstone of AbbVie’s business as a global biopharmaceutical company. Our focus is on developing medicines that can offer strong clinical performance and, provide measurable patient benefit—particularly in areas where there is significant need—such as hepatitis C, neuroscience, immunology, oncology, chronic kidney disease and gynecology.

AbbVie’s approach to scientific innovation builds on an impressive track record of developing breakthrough science. Our scientists discovered and developed two of the first medications to treat HIV infection, helping to change the outlook for many patients impacted by this disease. Our work in immunology has benefited patients with rheumatoid arthritis, psoriasis, Crohn’s disease and other chronic, autoimmune conditions. We continue to advance scientific research across many disease areas.

Partnerships Play a Key Role

We also know that some of the most important medical breakthroughs often result from collaborative R&D agreements and from partnerships. To find potential new therapies for patients we look both inside and outside AbbVie for promising discoveries. We partner and collaborate with peer companies, universities, non-governmental organisations, as well as other relevant groups, to help find solutions for patients around the globe—because we recognise there are times when we can accomplish more together than alone.


Therapeutic Focus Areas

Our core therapeutic areas include Virology, Neuroscience, Immunology, Oncology, Gynecology and General Medicine.


Devoted to New Discoveries

Our scientists are advancing a pipeline of specialty medicines with a focus on cancer, immune-mediated conditions, neurodegenerative diseases and more.